Page 2 - டொராண்டோ கண்டுபிடிப்பு விரைவுபடுத்துதல் கூட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டொராண்டோ கண்டுபிடிப்பு விரைவுபடுத்துதல் கூட்டாளர்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டொராண்டோ கண்டுபிடிப்பு விரைவுபடுத்துதல் கூட்டாளர்கள் Today - Breaking & Trending Today

Biotech company founded by University of Toronto researchers secures US$85 million in financing

Date Time
Biotech company founded by University of Toronto researchers secures US$85 million in financing
Juan Carlos Zúñiga-Pflücker (left), of the Temerty Faculty of Medicine and Sunnybrook Health Sciences Centre, and Peter Zandstra, who is now at UBC, founded Notch Therapeutics at U of T in 2018.
Notch was founded in 2018 by two pioneers of cell therapy research, Juan Carlos Zúñiga-Pflücker, chair of the department of immunology at the University of Toronto’s Temerty Faculty of Medicine and a senior scientist at Sunnybrook Health Sciences Centre, and Peter Zandstra, who was then at U of T and is now a professor at the University of British Columbia, but continues to collaborate with U of T’s Institute for Biomedical Engineering. The company was supported by MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine. ....

United Kingdom , British Columbia , Juan Carlos , Peter Zandstra , University Of British Columbia , T Institute For Biomedical Engineering , University Of Toronto Temerty Faculty Medicine , Sunnybrook Health Sciences Centre , Centre For Commercialization Of Regenerative Medicine , Notch Therapeutics , Temerty Faculty , Toronto Innovation Acceleration Partners , University Of Toronto , Regenerative Medicine , Cell Therapies , Cell Therapy , Immune Cells , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா , ஜுவான் கார்லோஸ் , பல்கலைக்கழகம் ஆஃப் பிரிட்டிஷ் கொலம்பியா , டி நிறுவனம் க்கு உயிர் மருத்துவ பொறியியல் , சன்னிபிரூக் ஆரோக்கியம் அறிவியல் மையம் , மையம் க்கு வணிகமயமாக்கல் ஆஃப் மீளுருவாக்கம் மருந்து , உச்சநிலை சிகிச்சை , டொராண்டோ கண்டுபிடிப்பு விரைவுபடுத்துதல் கூட்டாளர்கள் ,

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/
Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The finan ....

British Columbia , Peter Zandstra , Mary Moynihan , David Chang , University Of Toronto , Enterprises Holdings Ltd , Allogene Therapeutics Inc , Sunnybrook Research Institute , Centre For Commercialization Of Regenerative Medicine , Prnewswire Notch Therapeutics Inc , Allogene Therapeutics , Lumira Ventures , Holdings Ltd , Regenerative Medicine , Casdin Capital , Samsara Biocapital , Engineered Thymic Niche , David Main , Chief Executive Officer , Notch Board , Notch Therapeutics , Toronto Innovation Acceleration Partners , Notch Therapeutics Closes 85 Million Seriesa Financing To Develop Pipeline Of Renewable Stem Cell Derived Cancer Immunotherapies , பிரிட்டிஷ் கொலம்பியா , மேரி மாய்நீஹாந் , டேவிட் சாங் ,

Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences

Share this article
Share this article
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond, Ph.D. as Senior Vice President, Preclinical and Translational Sciences. Dr. Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering.
We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND, said David Main, President and Chief Executive Officer of Notch. Adding Chris to our leadership team will bolster our preclinical pipeline and translational research capabilities to accelerate development of the company s cell therapy candidates from discovery into clinical applicatio ....

British Columbia , Chris Bond , Mary Moynihan , Peter Zandstra , Sunnybrook Research Institute , Centre For Commercialization Of Regenerative Medicine , Translational Sciences , University Of Toronto , Oncomed Pharmaceuticals , University Of Washington , Notch Therapeutics Inc , Preclinical Translational Sciences , Senior Vice President , Vice President , David Main , Chief Executive Officer , Juno Therapeutics , Editas Medicine , Notch Therapeutics , Engineered Thymic Niche , Toronto Innovation Acceleration Partners , Regenerative Medicine , பிரிட்டிஷ் கொலம்பியா , கிறிஸ் பத்திரம் , மேரி மாய்நீஹாந் , சன்னிபிரூக் ஆராய்ச்சி நிறுவனம் ,